Comparison results
| Results: Differences General | ✘H18.3 | ✘Sarcoma of the orbit | |||||||||||||
| Related research | Analogs | Analogs | |||||||||||||
| |||||||||||||||
| Distinctive symptoms | |||||||||||||||
| Register, to see more distinctive signs of diseases and studies | 100% | — | |||||||||||||
| Register, to see more distinctive signs of diseases and studies | — | 100% | |||||||||||||
| fuchs syndrome | 90% | — | |||||||||||||
| sarcoma of the orbit | — | 92% | |||||||||||||
| worse after sleep | 68% | — | |||||||||||||
| lymphosarcoma | — | 73% | |||||||||||||
| blurred vision | 62% | — | |||||||||||||
| cancer | — | 68% | |||||||||||||
| general deterioration in the evening | 61% | — | |||||||||||||
| limitation of the mobility of the eyeballs | — | 65% | |||||||||||||
| in the evening blurry vision | 61% | — | |||||||||||||
| exophthalmos | — | 63% | |||||||||||||
| corneal edema | 60% | — | |||||||||||||
| oncology | — | 62% | |||||||||||||
| visual impairment | 58% | — | |||||||||||||
| congestion bursting pain in the eye | — | 62% | |||||||||||||
| glass eyes | 55% | — | |||||||||||||
| retinal atrophy | — | 49% | |||||||||||||
| worse in evening | 48% | — | |||||||||||||
| red eyelids | — | 48% | |||||||||||||
| vision blurs | 48% | — | |||||||||||||
| soft tissue sarcoma | — | 47% | |||||||||||||
| feeling of sand in the eyes | 47% | — | |||||||||||||
| swelling of eyelids | — | 47% | |||||||||||||
| sand in the eyes | 45% | — | |||||||||||||
| roth's disease | — | 46% | |||||||||||||
| blindness | 44% | — | |||||||||||||
| retinal hemorrhage | — | 46% | |||||||||||||
| a history of organ transplantation | 41% | — | |||||||||||||
| retinal dystrophy | — | 44% | |||||||||||||
| wet eyes | 41% | — | |||||||||||||
| optic nerve atrophy | — | 42% | |||||||||||||
| allergy to the sun | 39% | — | |||||||||||||
| hemorrhage in the eye | — | 42% | |||||||||||||
| lack of sleep | 38% | — | |||||||||||||
| nose large eyes | — | 41% | |||||||||||||
| corneal opacity | 38% | — | |||||||||||||
| bursting | — | 41% | |||||||||||||
| consequences of surgery | 36% | — | |||||||||||||
| fibrosarcoma | — | 40% | |||||||||||||
| swelling of the extremities | 35% | — | |||||||||||||
| angiopathy of the retina | — | 39% | |||||||||||||
| eye swelling | 34% | — | |||||||||||||
| pain in the eyes | — | 35% | |||||||||||||
| consequences of taking medications | 34% | — | |||||||||||||
| metastases | — | 35% | |||||||||||||
| feeling of danger | 33% | — | |||||||||||||
| up vascular mesh | — | 35% | |||||||||||||
| worse during sleep | 33% | — | |||||||||||||
| radiation therapy | — | 34% | |||||||||||||
| increased | 32% | — | |||||||||||||
| radiation damage | — | 33% | |||||||||||||
| dermatitis | 30% | — | |||||||||||||
| skin anesthesia | — | 33% | |||||||||||||
| poor sleep | 29% | — | |||||||||||||
| peptic ulcer | — | 33% | |||||||||||||
| worse in morning | 28% | — | |||||||||||||
| anesthesia | — | 32% | |||||||||||||
| onset of illness | 25% | — | |||||||||||||
| angiopathy | — | 30% | |||||||||||||
| drug disease | 25% | — | |||||||||||||
| s eyes cloudy | 31% | 37% | |||||||||||||
| corneal dystrophy | 71% | 48% | |||||||||||||
| keratopathy | 38% | 44% | |||||||||||||
| dystrophy | 60% | 47% | |||||||||||||
| gradual deterioration of the condition | 29% | 34% | |||||||||||||
| history of surgery | 48% | 38% | |||||||||||||
| helps others | 27% | 32% | |||||||||||||
| eye surgery | 45% | 37% | |||||||||||||
| swelling | 36% | 30% | |||||||||||||
Instructions
Video 
- Introduce new diseases through 🔍 Search and input on the top panel using
- The table shows the most important distinguishing symptoms, tests and diagnoses related to the selected diseases.
- The higher the percentage, the more important this symptom is for the disease and vice versa. At 0%, we can say that this symptom never occurs in the disease.
- The list changes dynamically depending on the data of the current visit in the selection of therapy .
- Click on the percentageto see the suggestions from the original source.
- By using the service, you agree to user agreement.
